Pactiv Evergreen Inc. Announces Receipt of All Required Regulatory Approvals for Planned Acquisition by Novolex
1. Pactiv Evergreen to be acquired by Novolex for $18.00 per share. 2. Transaction expected to close on April 1, 2025, pending conditions. 3. Post-acquisition, Pactiv Evergreen will delist from Nasdaq and become privately held. 4. Goldman Sachs and Lazard Frères are acting as financial advisors. 5. Forward-looking statements caution against depending solely on projections.